Delphia Therapeutics
Kevin Marks currently serves as President and CEO of Delphia Therapeutics and has been with the company since July 2022. Marks co-founded the company and also holds advisory roles at GV, starting in April 2022. Previously, Marks was the Head of Oncology Drug Discovery at Novartis Institutes for BioMedical Research from September 2020 to March 2022, overseeing a team focused on various oncology indications. Marks spent over eleven years at Agios Pharmaceuticals, culminating in the role of Vice President of Biology, where responsibilities included supporting oncology and rare genetic diseases initiatives. Earlier career experiences include senior scientific roles at Makoto Life Sciences and Curis. Marks earned a PhD in Molecular Pharmacology/Chemical & Systems Biology from Stanford University and a BA in Biology from Cornell University.
This person is not in any teams
Delphia Therapeutics
Delphia Therapeutics is a biotechnology company pioneering activation lethality, a new area of cancer therapeutics that target cancer's surprising vulnerability to oncogene overactivation. Delphia’s activation lethality platform offers the potential for first-in-class targeted cancer medicines that are effective on their own while also combating the emergence of drug resistance to classic targeted therapies.